Curcumin and Gastric Cancer: a Review on Mechanisms of Action

  • Tohid Hassanalilou
  • Saeid Ghavamzadeh
  • Leila KhaliliEmail author
Review Article


Background and Aim

Gastric cancer, as the fourth cause of death in women and third in men with malignant tumors, is now threatening people’s lives worldwide. Natural anti-tumor products are potential anti-cancer agents with fewer by-effects. Curcumin, an herbal product, has been used as a cosmetic and food additive and as a traditional herbal medicine for thousands of years in Asian countries. Several studies revealed that curcumin can inhibit the invasion and proliferation of gastric cancer cells. This paper analyzes existing data from animal and in vitro studies in order to highlight the mechanisms of therapeutic effects of curcumin in gastric cancer.


Science Direct and Pub Med databases were searched by using “curcumin” and “gastric cancer” for searching the studies aiming the application of curcumin and the beneficial effects of curcumin in gastric cancer control and treatment.


These results suggested that curcumin can suppress multiple signaling pathways and inhibit cancer cell proliferation, invasion, metastasis, and angiogenesis. According to the studies, curcumin can inhibit gastric cancer by several mechanisms including decreasing proliferation, inducing apoptosis, and reducing chemo-resistance in gastric cancer cells.


The findings of present paper provided novel perceptions about the mechanisms of curcumin action in gastric cancer cell growth inhibition and its therapeutic strategies for gastric cancer control. So, curcumin could be considered as a novel therapeutic strategy to control gastric cancer cell growth.


Curcumin Gastric cancer Mechanisms 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Xiao X-y, Hao M, X-y Y, Ba Q, Li M, Ni S-j, et al. Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis. Cancer Lett. 2011;302(1):69–75.Google Scholar
  2. 2.
    Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Cancer Netw. 2010;8(4):437–47.Google Scholar
  3. 3.
    Maleki D, Homayouni A, Khalili L, Golkhalkhali B. Probiotics in cancer prevention, updating the evidence. Probiotics, Prebiotics, and Synbiotics: Bioactive Foods in Health Promotion. 2015:781–91. Google Scholar
  4. 4.
    Dennis T, Fanous M, Mousa S. Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer. 2009;61(5):587–97.Google Scholar
  5. 5.
    Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097–116.Google Scholar
  6. 6.
    Kewitz S, Volkmer I, Staege MS. Curcuma contra cancer? Curcumin and Hodgkin’s lymphoma. Cancer Growth Metastasis. 2013;6:35.Google Scholar
  7. 7.
    Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218.Google Scholar
  8. 8.
    Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. InThe molecular targets and therapeutic uses of curcumin in health and disease. Boston, MA: Springer; 2007. p. 1–75. Google Scholar
  9. 9.
    Zhou X, Wang W, Li P, Zheng Z, Tu Y, Zhang Y, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in inducing gastric cancer cell apoptosis both in vitro and in vivo. Oncol Res. 2016;23(1–2):29–34.Google Scholar
  10. 10.
    Li W, Zhou Y, Yang J, Li H, Zhang H, Zheng P. Curcumin induces apoptotic cell death and protective autophagy in human gastric cancer cells. Oncol Rep. 2017;37(6):3459–66.Google Scholar
  11. 11.
    Azuine M, Kayal J, Bhide S. Protective role of aqueous turmeric extract against mutagenicity of direct-acting carcinogens as well as benzo [a] pyrene-induced genotoxicity and carcinogenicity. J Cancer Res Clin Oncol. 1992;118(6):447–52.Google Scholar
  12. 12.
    Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, et al. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res. 2008;68(6):1962–9.Google Scholar
  13. 13.
    Moragoda L, Jaszewski R, Majumdar AP. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Gastroenterology. 2001;120(5):A666.Google Scholar
  14. 14.
    Gao C, Ding Z, Liang B, Chen N, Cheng D. Study on the effects of curcumin on angiogenesis. Zhong Yao Cai. 2003;26(7):499–502.Google Scholar
  15. 15.
    Cai X-Z, Wang J, Xiao-Dong L, Wang G-L, Liu F-N, Cheng M-S, et al. Curcumin suppresses proliferation and invasion in human gastric cancer cells by down-regulation of PAK1 activity and cyclin D1 expression. Cancer Biol Ther. 2009;8(14):1360–8.Google Scholar
  16. 16.
    Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res. 2012;5(2):205–15.Google Scholar
  17. 17.
    Yu L-L, Wu J-G, Dai N, Yu H-G, Si J-Μ. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-κB transcription factor. Oncol Rep. 2011;26(5):1197–203.Google Scholar
  18. 18.
    Koo JY, Kim HJ, Jung K-O, Park K-Y. Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food. 2004;7(2):117–21.Google Scholar
  19. 19.
    Qin H, Wei L, Zhang J, Tang J. Study on functions and mechanism of curcumin in inducing gastric carcinoma BGC apoptosis. Chinese journal of cellular and molecular immunology. 2011;27(11):1227–30.Google Scholar
  20. 20.
    Cai X, Huang W, Qiao Y, Du S, Chen Y, Chen D, et al. Inhibitory effects of curcumin on gastric cancer cells: a proteomic study of molecular targets. Phytomedicine. 2013;20(6):495–505.Google Scholar
  21. 21.
    Hasan M, Belhaj N, Benachour H, Barberi-Heyob M, Kahn C, Jabbari E, et al. Liposome encapsulation of curcumin: physico-chemical characterizations and effects on MCF7 cancer cell proliferation. Int J Pharm. 2014;461(1):519–28.Google Scholar
  22. 22.
    Gostjeva EV, Thilly WG. Stem cell stages and the origins of colon cancer. Stem Cell Rev. 2005;1(3):243–51.Google Scholar
  23. 23.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100(7):3983–8.Google Scholar
  24. 24.
    Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65(20):9328–37.Google Scholar
  25. 25.
    Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946–51.Google Scholar
  26. 26.
    Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 2005;7(11):967–76.Google Scholar
  27. 27.
    Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.Google Scholar
  28. 28.
    Mirzaei M, Mahmoodi M, Hajizadeh M, Bagrezaei F, Akbarpoor V, Bahramabadi R. The survay of curcumin effect on the expressional profile of OCT4, Nanog and Nucleostemin genes in AGS (adenocarcinoma) cancer cell line. Community Health J. 2014;8(2):19–27.Google Scholar
  29. 29.
    Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11.Google Scholar
  30. 30.
    Avery S, Inniss K, Moore H. The regulation of self-renewal in human embryonic stem cells. Stem Cells Dev. 2006;15(5):729–40.Google Scholar
  31. 31.
    Yazd EF, Rafiee MR, Soleimani M, Tavallaei M, Salmani MK, Mowla SJ. OCT4B1, a novel spliced variant of OCT4, generates a stable truncated protein with a potential role in stress response. Cancer Lett. 2011;309(2):170–5.Google Scholar
  32. 32.
    Kern MJ, Argao EA, Potter SS. Homeobox genes and heart development. Trends Cardiovasc Med. 1995;5(2):47–54.Google Scholar
  33. 33.
    Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol. 2007;9(6):625–35.Google Scholar
  34. 34.
    Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer. 2006;6(6):459–71.Google Scholar
  35. 35.
    Nheu TV, He H, Hirokawa Y, Tamaki K, Florin L, Schmitz ML, et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family, selectively block the growth of HAS transformants. Cancer J. 2002;8(4):328–36.Google Scholar
  36. 36.
    Eswaran J, Lee WH, Debreczeni JÉ, Filippakopoulos P, Turnbull A, Fedorov O, et al. Crystal structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure. 2007;15(2):201–13.Google Scholar
  37. 37.
    Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, et al. OSU03012, a celecoxib derivative, directly targets p21 activated kinase. Mol Pharmacol. 2007..Google Scholar
  38. 38.
    Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem. 2003;72(1):743–81.Google Scholar
  39. 39.
    Arias-Romero LE, Chernoff J. A tale of two Paks. Biol Cell. 2008;100(2):97–108.Google Scholar
  40. 40.
    Balasenthil S, Sahin AA, Barnes CJ, Wang R-A, Pestell RG, Vadlamudi RK, et al. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem. 2004;279(2):1422–8.Google Scholar
  41. 41.
    Haghi A, Azimi H, Rahimi R. A comprehensive review on pharmacotherapeutics of three phytochemicals, curcumin, quercetin, and Allicin, in the treatment of gastric cancer. J Gastrointest Cancer. 2017;48(4):314–20.Google Scholar
  42. 42.
    Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20(5):187–90.Google Scholar
  43. 43.
    Joyce D, Bouzahzah B, Fu M, Albanese C, D’Amico M, Steer J, et al. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-κB-dependent pathway. J Biol Chem. 1999;274(36):25245–9.Google Scholar
  44. 44.
    Foryst-Ludwig A, Naumann M. p21-activated kinase 1 activates the nuclear factor κB (NF-κB)-inducing kinase-IκB kinases NF-κB pathway and proinflammatory cytokines in helicobacter pylori infection. J Biol Chem. 2000;275(50):39779–85.Google Scholar
  45. 45.
    Wong R. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30(1):87.Google Scholar
  46. 46.
    Li Y, Zhang S, Geng J-X, Hu X-Y. Curcumin inhibits human non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome C. Asian Pac J Cancer Prev. 2013;14(8):4599–602.Google Scholar
  47. 47.
    Singh DV, Agarwal S, Singh P, Godbole MM, Misra K. Curcumin conjugates induce apoptosis via a mitochondrion dependent pathway in MCF-7 and MDA-MB-231 cell lines. Asian Pac J Cancer Prev. 2013;14(10):5797–804.Google Scholar
  48. 48.
    Gopal PK, Paul M, Paul S. Curcumin induces caspase mediated apoptosis in JURKAT cells by disrupting the redox balance. Asian Pac J Cancer Prev APJCP. 2013;15(1):93–100.Google Scholar
  49. 49.
    Zhang G-H, Cai L-J, Wang Y-F, Zhou Y-H, An Y-F, Liu Y-C, et al. Novel compound PS-101 exhibits selective inhibition in non-small-cell lung cancer cell by blocking the EGFR-driven antiapoptotic pathway. Biochem Pharmacol. 2013;86(12):1721–30.Google Scholar
  50. 50.
    Wang Y-Q, Zhang S-J, Lu H, Yang B, Ye L-F, Zhang R-SAC. 21-steroidal glycoside isolated from the roots of Cynanchum auriculatum induces cell cycle arrest and apoptosis in human gastric cancer sgc-7901 cells. Evid Based Complement Alternat Med. 2013;2013:1–7.Google Scholar
  51. 51.
    Tomek M, Akiyama T, Dass CR. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. J Pharm Pharmacol. 2012;64(12):1695–702.Google Scholar
  52. 52.
    Liu B, Xu N, Man Y, Shen H, Avital I, Stojadinovic A, et al. Apoptosis in living animals is assisted by scavenger cells and thus may not mainly go through the cytochrome C-caspase pathway. J Cancer. 2013;4(9):716–23.Google Scholar
  53. 53.
    Méndez J, Morales Cruz M, Delgado Y, Figueroa CM, Orellano EA, Morales M, et al. Delivery of chemically glycosylated cytochrome c immobilized in mesoporous silica nanoparticles induces apoptosis in HeLa cancer cells. Mol Pharm. 2013;11(1):102–11.Google Scholar
  54. 54.
    Sharoar MG, Islam MI, Shahnawaz M, Shin SY, Park I-S. Amyloid β binds procaspase-9 to inhibit assembly of Apaf-1 apoptosome and intrinsic apoptosis pathway. Biochim Biophys Acta (BBA) Mol Cell Res. 2014;1843(4):685–93.Google Scholar
  55. 55.
    Tyagi M, Bhattacharyya R, Bauri AK, Patro BS, Chattopadhyay S. DNA damage dependent activation of checkpoint kinase-1 and mitogen-activated protein kinase-p38 are required in malabaricone C-induced mitochondrial cell death. Biochim Biophys Acta Gen Subj. 2014;1840(3):1014–27.Google Scholar
  56. 56.
    Ma J-Q, Ding J, Zhang L, Liu C-M. Hepatoprotective properties of sesamin against CCl 4 induced oxidative stress-mediated apoptosis in mice via JNK pathway. Food Chem Toxicol. 2014;64:41–8.Google Scholar
  57. 57.
    Gajek A, Denel M, Bukowska B, Rogalska A, Marczak A. Pro-apoptotic activity of new analog of anthracyclines–WP 631 in advanced ovarian cancer cell line. Toxicol in Vitro. 2014;28(2):273–81.Google Scholar
  58. 58.
    Xue X, Yu J-L, Sun D-Q, Kong F, Qu X, Zou W, et al. Curcumin induces apoptosis in SGC-7901 gastric adenocarcinoma cells via regulation of mitochondrial signaling pathways. Asian Pac J Cancer Prev. 2013;15(9):3987–92.Google Scholar
  59. 59.
    Zhang C, Yuan X-r, Li H-y, Zhao Z-j, Liao Y-w, Wang X-y, et al. Downregualtion of dynamin-related protein 1 attenuates glutamate-induced excitotoxicity via regulating mitochondrial function in a calcium dependent manner in HT22 cells. Biochem Biophys Res Commun. 2014;443(1):138–43.Google Scholar
  60. 60.
    Aporta A, Catalán E, Galán-Malo P, Ramírez-Labrada A, Pérez M, Azaceta G, et al. Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors. Biochem Pharmacol. 2014;87(3):410–23.Google Scholar
  61. 61.
    Chan SL, Yu VC. Proteins of the BCL-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol. 2004;31(3):119–28.Google Scholar
  62. 62.
    Liu Z, Lu H, Jiang Z, Pastuszyn A, Chien-an AH. Apolipoprotein L6, a novel proapoptotic Bcl-2 homology 3–only protein, induces mitochondria-mediated apoptosis in cancer cells 1 1 Howard Hughes Medical Institute research aids to University of New Mexico Cancer Research and Treatment Center, American Cancer Society ACS-IRG-192 grant 412488–00095, and University of New Mexico Research Allocation Committee grant C-2222-RAC (CA. A. Hu). Mol Cancer Res. 2005;3(1):21–31.Google Scholar
  63. 63.
    Ko J-K, Choi K-H, Peng J, He F, Zhang Z, Weisleder N, et al. Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms. J Biol Chem. 2011;286(11):9038–48.Google Scholar
  64. 64.
    Lucena FRS, de Araújo LC, Rodrigues MD, da Silva TG, Pereira VR, Militão GC, et al. Induction of cancer cell death by apoptosis and slow release of 5-fluoracil from metal-organic frameworks Cu-BTC. Biomed Pharmacother. 2013;67(8):707–13.Google Scholar
  65. 65.
    Luo C, Du Z, Wei X, Chen G, Fu Z. Bisdemethoxycurcumin attenuates gastric adenocarcinoma growth by inducing mitochondrial dysfunction. Oncol Lett. 2015;9(1):270–4.Google Scholar
  66. 66.
    Hu H, Zhang Z, Zhao J, Wang T, Xu Y. Effect of opening of mitochondrial ATP-sensitive K+ channel on the distribution of cytochrome C and on proliferation of human pulmonary arterial smooth muscle cells in hypoxia. Sheng li xue bao. 2006;58(3):262–8.Google Scholar
  67. 67.
    Bodenstine TM, Vaidya KS, Ismail A, Beck BH, Diers AR, Edmonds MD, et al. Subsets of ATP-sensitive potassium channel (K ATP) inhibitors increase gap junctional intercellular communication in metastatic cancer cell lines independent of SUR expression. FEBS Lett. 2012;586(1):27–31.Google Scholar
  68. 68.
    Zhang S, Zhou F, Ding JH, Zhou XQ, Sun XL, Hu G. ATP-sensitive potassium channel opener iptakalim protects against MPP+-induced astrocytic apoptosis via mitochondria and mitogen-activated protein kinase signal pathways. J Neurochem. 2007;103(2):569–79.Google Scholar
  69. 69.
    Garg V, Hu K. Protein kinase C isoform-dependent modulation of ATP-sensitive K+ channels in mitochondrial inner membrane. Am J Phys Heart Circ Phys. 2007;293(1):H322–H32.Google Scholar
  70. 70.
    Ru Q, Tian X, Wu Y-X, Wu R-H, Pi M-S, Li C-Y. Voltage-gated and ATP-sensitive K+ channels are associated with cell proliferation and tumorigenesis of human glioma. Oncol Rep. 2014;31(2):842–8.Google Scholar
  71. 71.
    Liu X, Sun K, Song A, Zhang X, Zhang X, He X. Curcumin inhibits proliferation of gastric cancer cells by impairing ATP-sensitive potassium channel opening. World J Surg Oncol. 2014;12(1):389.Google Scholar
  72. 72.
    Tang X-q, Bi H, Feng J-q, Cao J-g. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin. 2005;26(8):1009–16.Google Scholar
  73. 73.
    Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets. 2000;1(1):85–99.Google Scholar
  74. 74.
    Hamilton KO, Topp E, Makagiansar I, Siahaan T, Yazdanian M, Audus KL. Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001;298(3):1199–205.Google Scholar
  75. 75.
    Arceci RJ. Tumor cell survival and resistance to therapy. Curr Opin Hematol. 1996;3(4):279–87.Google Scholar
  76. 76.
    Huang R, Yu H, Hu F, Tian S. Strategy to enhance efficacy of doxorubicin by curcumin as a potent Pgp inhibitor in gastric cancer. Biomedical Research. 2017;28(3):1231-6.Google Scholar
  77. 77.
    Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999;93(3):1075–85.Google Scholar
  78. 78.
    Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci. 1998;95(12):7024–9.Google Scholar
  79. 79.
    Bielak-Żmijewska A, Piwocka K, Magalska A, Sikora E. P-glycoprotein expression does not change the apoptotic pathway induced by curcumin in HL-60 cells. Cancer Chemother Pharmacol. 2004;53(2):179–85.Google Scholar
  80. 80.
    Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC, et al. MEKK3 expression correlates with nuclear factor κ B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer. 2009;115(17):3897–908.Google Scholar
  81. 81.
    Gangadharan C, Thoh M, Manna SK. Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis (vol 107, pg 203, 2009). J Cell Biochem. 2012;113(10):3299.Google Scholar
  82. 82.
    Ammann JU, Haag C, Kasperczyk H, Debatin KM, Fulda S. Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-κB inhibition. Int J Cancer. 2009;124(6):1301–11.Google Scholar
  83. 83.
    Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, et al. Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt’s lymphoma cell lines. Mol Cancer Ther. 2008;7(10):3318–29.Google Scholar
  84. 84.
    Yu L-L, Dai N, Yu H-G, Sun L-M, Si J-M. Akt associates with nuclear factor κB and plays an important role in chemoresistance of gastric cancer cells. Oncol Rep. 2010;24(1):113–9.Google Scholar
  85. 85.
    Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441(7092):431–6.Google Scholar
  86. 86.
    Bordoloi D, Kunnumakkara AB. The Potential of Curcumin: A Multitargeting Agent in Cancer Cell Chemosensitization. InRole of Nutraceuticals in Cancer Chemosensitization. 2018;31–60.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Nutrition, Faculty of Nutrition and Food SciencesTabriz University of Medical SciencesTabrizIran
  2. 2.Department of Human Nutrition, Medicine FacultyUrmia University of Medical SciencesUrmiaIran

Personalised recommendations